We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merit Medical (MMSI) Rallies 4.8% Post Q3 Earnings Beat
Read MoreHide Full Article
Merit Medical Systems, Inc. (MMSI - Free Report) soared 4.8% on Oct 29 after reporting third-quarter 2020 adjusted earnings per share (EPS) of 42 cents, which beat the Zacks Consensus Estimate of 19 cents by a massive 121.1%. Moreover, the bottom line rose 50% from the year-ago quarter.
Revenues in Details
This Utah-based provider of peripheral and cardiac intervention products reported worldwide revenues of $243.9 million, up 0.4% from the year-ago quarter. On a comparable constant-currency basis, the figure fell 0.1% year over year. The top line surpassed the Zacks Consensus Estimate of $219 million by 11.4%.
The Cardiovascular unit reported third-quarter revenues of $236.4 million, up 0.8% year over year due to an increase of 3% in Peripheral Intervention revenues to $86.8 million. Moreover, revenues from Custom Procedural Solutions rose 22% to $56.4 million. However, revenues from Cardiac Intervention fell 7.7% to $69.1 million. Also, OEM revenues contracted 17% to $24.1 million.
Revenues from the Endoscopy devices totaled $7.6 million, down 12.3% year over year.
Margins
In the quarter under review, gross profit totaled $102 million, down 2% on a year-over-year basis. Gross margin came in at 41.8% of net revenues, down 103 basis points (bps) year over year.
Adjusted operating profit totaled $16.3 million, up 7549.3% year over year.
Adjusted operating margin in the quarter came in at 6.7%, indicating an expansion of 659 bps year over year.
Merit Medical Systems, Inc. Price, Consensus and EPS Surprise
The company exited the third quarter with cash and cash equivalents of $44.6 million, down from $49.7 million at the end of the second quarter.
2020 Guidance
Net revenues for 2020 are projected within the range of $950 million to $959 million, indicating a decrease of around 3.5% to 4.5% year over year. The Zacks Consensus Estimate for the same is pegged at $937.9 million.
Adjusted EPS for 2020 is pegged within the range of $1.52 to $1.57. The Zacks Consensus Estimate for the same is pegged at $1.28.
Wrapping Up
Merit Medical exited the third quarter of 2020 on a strong note. It saw overall revenue growth within its Cardiovascular unit. The company is on track to complete the movement of more than 14 production lines and consolidate several facilities before year-end. The CE mark for the Merit WRAPSODY Endoprosthesis Stent System and its commercialization in the European Union continues to buoy optimism. The recent FDA approval for the WRAPSODY Arterial Venous access Efficacy (WAVE) IDE trial is encouraging.
The acquisitions of Cianna Medical and Vascular Insights continue to contribute. Further, the company stands to benefit from the execution of its global growth and profitability plan. A robust pipeline of new products and other internally-developed products instill investor optimism in the stock. Despite COVID-19, the company has witnessed robust demand for several of its critical care products, such as hemodynamic monitoring, peritoneal dialysis catheters and insertion tools apart from its infection control products.
However, we are concerned about the revenue decline at its Endoscopy segment. Contraction in gross margin is a concern as well. Also, stiff competition and higher consolidation in the healthcare industry are dampeners. Further, economic stagnation due to the outbreak adds to the woes.
Zacks Rank and Other Key Picks
Merit Medical currently holds a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space that have already announced their quarterly results are Thermo Fisher Scientific Inc. (TMO - Free Report) , Align Technology, Inc. (ALGN - Free Report) and AngioDynamics, Inc. (ANGO - Free Report) . While Align Technology sports a Zacks Rank #1 (Strong Buy), the other two carry a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher reported third-quarter 2020 adjusted EPS of $5.63, beating the Zacks Consensus Estimate by 28.8%. Revenues of $8.52 billion surpassed the consensus mark by 10%.
Align Technology reported third-quarter 2020 adjusted EPS of $2.25, which surpassed the Zacks Consensus Estimate by 281.4%. Revenues of $734.1 million outpaced the consensus mark by 38%.
AngioDynamics reported first-quarter fiscal 2021 adjusted EPS of 2 cents against the Zacks Consensus Estimate of a loss per share of 6 cents. Revenues of $70.2 million beat the consensus mark by 6.9%.
Have You Seen Zacks’ 2020 Election Stock Report?
The upcoming election could be a massive buying opportunity for savvy investors. Trillions of dollars will shift into new market sectors after the election. The question is, which sectors will soar for each candidate? Zacks has put together a new special report to help readers like you target big profits.
The 2020 Election Stock Report reveals specific stocks you’ll want to own immediately after the results are announced – 6 if Trump wins, 6 if Biden wins. Past election reports have led investors to gains of +71%, +83%, even +185% in the following months. This year’s picks could be even more lucrative.
Image: Bigstock
Merit Medical (MMSI) Rallies 4.8% Post Q3 Earnings Beat
Merit Medical Systems, Inc. (MMSI - Free Report) soared 4.8% on Oct 29 after reporting third-quarter 2020 adjusted earnings per share (EPS) of 42 cents, which beat the Zacks Consensus Estimate of 19 cents by a massive 121.1%. Moreover, the bottom line rose 50% from the year-ago quarter.
Revenues in Details
This Utah-based provider of peripheral and cardiac intervention products reported worldwide revenues of $243.9 million, up 0.4% from the year-ago quarter. On a comparable constant-currency basis, the figure fell 0.1% year over year. The top line surpassed the Zacks Consensus Estimate of $219 million by 11.4%.
The Cardiovascular unit reported third-quarter revenues of $236.4 million, up 0.8% year over year due to an increase of 3% in Peripheral Intervention revenues to $86.8 million. Moreover, revenues from Custom Procedural Solutions rose 22% to $56.4 million. However, revenues from Cardiac Intervention fell 7.7% to $69.1 million. Also, OEM revenues contracted 17% to $24.1 million.
Revenues from the Endoscopy devices totaled $7.6 million, down 12.3% year over year.
Margins
In the quarter under review, gross profit totaled $102 million, down 2% on a year-over-year basis. Gross margin came in at 41.8% of net revenues, down 103 basis points (bps) year over year.
Adjusted operating profit totaled $16.3 million, up 7549.3% year over year.
Adjusted operating margin in the quarter came in at 6.7%, indicating an expansion of 659 bps year over year.
Merit Medical Systems, Inc. Price, Consensus and EPS Surprise
Merit Medical Systems, Inc. price-consensus-eps-surprise-chart | Merit Medical Systems, Inc. Quote
Financial Update
The company exited the third quarter with cash and cash equivalents of $44.6 million, down from $49.7 million at the end of the second quarter.
2020 Guidance
Net revenues for 2020 are projected within the range of $950 million to $959 million, indicating a decrease of around 3.5% to 4.5% year over year. The Zacks Consensus Estimate for the same is pegged at $937.9 million.
Adjusted EPS for 2020 is pegged within the range of $1.52 to $1.57. The Zacks Consensus Estimate for the same is pegged at $1.28.
Wrapping Up
Merit Medical exited the third quarter of 2020 on a strong note. It saw overall revenue growth within its Cardiovascular unit. The company is on track to complete the movement of more than 14 production lines and consolidate several facilities before year-end. The CE mark for the Merit WRAPSODY Endoprosthesis Stent System and its commercialization in the European Union continues to buoy optimism. The recent FDA approval for the WRAPSODY Arterial Venous access Efficacy (WAVE) IDE trial is encouraging.
The acquisitions of Cianna Medical and Vascular Insights continue to contribute. Further, the company stands to benefit from the execution of its global growth and profitability plan. A robust pipeline of new products and other internally-developed products instill investor optimism in the stock. Despite COVID-19, the company has witnessed robust demand for several of its critical care products, such as hemodynamic monitoring, peritoneal dialysis catheters and insertion tools apart from its infection control products.
However, we are concerned about the revenue decline at its Endoscopy segment. Contraction in gross margin is a concern as well. Also, stiff competition and higher consolidation in the healthcare industry are dampeners. Further, economic stagnation due to the outbreak adds to the woes.
Zacks Rank and Other Key Picks
Merit Medical currently holds a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space that have already announced their quarterly results are Thermo Fisher Scientific Inc. (TMO - Free Report) , Align Technology, Inc. (ALGN - Free Report) and AngioDynamics, Inc. (ANGO - Free Report) . While Align Technology sports a Zacks Rank #1 (Strong Buy), the other two carry a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher reported third-quarter 2020 adjusted EPS of $5.63, beating the Zacks Consensus Estimate by 28.8%. Revenues of $8.52 billion surpassed the consensus mark by 10%.
Align Technology reported third-quarter 2020 adjusted EPS of $2.25, which surpassed the Zacks Consensus Estimate by 281.4%. Revenues of $734.1 million outpaced the consensus mark by 38%.
AngioDynamics reported first-quarter fiscal 2021 adjusted EPS of 2 cents against the Zacks Consensus Estimate of a loss per share of 6 cents. Revenues of $70.2 million beat the consensus mark by 6.9%.
Have You Seen Zacks’ 2020 Election Stock Report?
The upcoming election could be a massive buying opportunity for savvy investors. Trillions of dollars will shift into new market sectors after the election. The question is, which sectors will soar for each candidate? Zacks has put together a new special report to help readers like you target big profits.
The 2020 Election Stock Report reveals specific stocks you’ll want to own immediately after the results are announced – 6 if Trump wins, 6 if Biden wins. Past election reports have led investors to gains of +71%, +83%, even +185% in the following months. This year’s picks could be even more lucrative.
Check out Zacks’ 2020 Election Stock Report >>